Our development program is guided by scientific evidence and clinical excellence. Following more than 20 years of research, successful evaluation in three preclinical animal models, and completion of a Phase 1a Safety Trial demonstrating non-toxicity, Amnio Bio is advancing into Phase 1b/2a Clinical Development to establish the optimal dosage and evaluate efficacy in humans.
Every milestone strengthens our commitment to delivering a safe and effective regenerative therapy for stroke recovery.
Innovation thrives through collaboration. Amnio Bio works closely with leading research institutions, healthcare organisations, manufacturing partners, and clinical experts to accelerate the development and delivery of this innovative therapy.
These partnerships provide the scientific expertise, manufacturing capability, and clinical infrastructure needed to support future manufacturing excellence within regulatory guidelines and global accessibility.
Our platform is built for long-term accessibility. By establishing a strong manufacturing and distribution network, we are creating the infrastructure needed to produce high-quality cell therapies at scale and deliver them efficiently through healthcare systems worldwide. Our goal is to ensure that transformative regenerative treatments reach the patients who need them most.
